Anti-interferon-gamma polyclonal antibody - Advanced Biotherapy

Drug Profile

Anti-interferon-gamma polyclonal antibody - Advanced Biotherapy

Alternative Names: A-IFN-gamma; anti-IFN-γ; Anti-IFN-γ polyclonal antibody - Advanced Biotherapy

Latest Information Update: 02 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Advanced Biotherapy
  • Class Polyclonal antibodies
  • Mechanism of Action Interferon gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratoplasty rejection

Highest Development Phases

  • Discontinued Alopecia; Epidermolysis bullosa; Herpes simplex virus infections; Keratoplasty rejection; Multiple sclerosis; Pemphigus vulgaris; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Type 1 diabetes mellitus; Uveitis; Vitiligo

Most Recent Events

  • 14 Jul 2005 Data presented at the Annual European Congress of Rheumatology (EULAR-2005) have been added to the adverse events and Rheumatic Disease therapeutic trials sections
  • 21 Jan 2005 Data from a media release have been added to the Viral infections therapeutic trials section
  • 28 Oct 2004 Data from a media release have been added to the Viral Infections therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top